Disruptive Pharma AB (FRA:5LH0) Other Current Liabilities: €0.02 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5LH0 Disruptive Pharma AB FRA:5LH0
4 GF Score
Price €0.09
View Full Analysis

What is Disruptive Pharma AB Other Current Liabilities?

Disruptive Pharma AB FRA:5LH0 -0.92% 4 Other Current Liabilities is €0.02 Mil as of Jun. 2026. GuruFocus rates FRA:5LH0 with a GF Score™ of 4/100.

Disruptive Pharma AB's other current liabilities for the quarter that ended in Jun. 2026 was €0.02 Mil.

Disruptive Pharma AB's quarterly other current liabilities declined from Dec. 2025 (€0.32 Mil) to Mar. 2026 (€0.22 Mil) and declined from Mar. 2026 (€0.22 Mil) to Jun. 2026 (€0.02 Mil).

Disruptive Pharma AB's annual other current liabilities increased from Dec. 2023 (€0.26 Mil) to Dec. 2024 (€0.26 Mil) and increased from Dec. 2024 (€0.26 Mil) to Dec. 2025 (€0.32 Mil).

Disruptive Pharma AB Other Current Liabilities Related Terms

Disruptive Pharma AB Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Disruptive Pharma AB's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Disruptive Pharma AB Other Current Liabilities Chart

Disruptive Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.22 0.26 0.26 0.32

Disruptive Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.03 0.32 0.22 0.02
FRA:5LH0
4GF Score
Disruptive Pharma AB FRA:5LH0
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Disruptive Pharma AB Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €0.02 Mil mean?
Disruptive Pharma AB (FRA:5LH0) has a Other Current Liabilities of €0.02 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Disruptive Pharma AB.
Is Disruptive Pharma AB's Other Current Liabilities too high?
Disruptive Pharma AB's current Other Current Liabilities is €0.02 Mil. Overall, Disruptive Pharma AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Disruptive Pharma AB's Other Current Liabilities compare to ?
Disruptive Pharma AB's Other Current Liabilities of €0.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Disruptive Pharma AB. Disruptive Pharma AB's current Other Current Liabilities is €0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disruptive Pharma AB stock overvalued right now?
Disruptive Pharma AB (FRA:5LH0) has a current Other Current Liabilities of €0.02 Mil. The current Other Current Liabilities is €0.02 Mil. Disruptive Pharma AB's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Disruptive Pharma AB (FRA:5LH0), the current Other Current Liabilities is €0.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Disruptive Pharma AB Business Description

Comparable Companies
Other Exchanges DPHA:Sweden
Address Dag Hammarskjold Road 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Disruptive Pharma AB is a Swedish drug delivery technology company developing and commercializing Formulite, a patented platform based on mesoporous magnesium carbonate (MMC). The platform is designed to improve the solubility, oral bioavailability and other properties of pharmaceutical compounds. The company's business model is based on contract development, partnerships and licensing arrangements with pharmaceutical and biotechnology companies for the development and commercialization of drug products optimized with Formulite.
4GF Score

Get the complete analysis for FRA:5LH0

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price